Core Insights - The core viewpoint of the article highlights the financial performance of Jianmin Group for the third quarter of 2025, indicating a decline in both revenue and net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company's operating revenue was 747 million yuan, a year-on-year decrease of 14.27% [1] - The net profit for Q3 2025 was 65.11 million yuan, down 20.84% year-on-year [1] - For the first three quarters of 2025, the total operating revenue reached 2.552 billion yuan, reflecting an 11.43% decline compared to the same period last year [1] - The net profit for the first three quarters was 286 million yuan, which is an 11.16% decrease year-on-year [1] - The basic earnings per share stood at 1.88 yuan [1] Segment Performance - The pharmaceutical manufacturing segment experienced a year-on-year growth of 19.67%, attributed to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue, down 36.91%, due to the company's ongoing optimization of its commercial subsidiaries' business structure, leading to a reduction in low-margin and inefficient operations [1]

Financial Performance - The company's operating revenue for the third quarter was ¥747,334,981.28, a decrease of 14.27% compared to the same period last year[4] - The total profit for the quarter was ¥66,529,235.86, down 23.73% year-on-year[4] - The net profit attributable to shareholders was ¥65,111,696.75, reflecting a decline of 20.84% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥60,222,741.34, a decrease of 21.29% year-on-year[4] - The basic earnings per share for the quarter was ¥0.42, down 22.22% from the same period last year[5] - The weighted average return on equity decreased by 0.95 percentage points to 2.55%[5] - The company's net profit for the current period is CNY 288,603,789.34, a decrease of 11.09% compared to CNY 324,587,553.14 in the previous period[21] - Operating profit for the current period is CNY 304,365,030.94, down from CNY 352,785,660.72, reflecting a decline of 13.71%[21] - Total revenue from sales of goods and services for the current period is CNY 2,680,603,615.88, compared to CNY 3,120,748,668.08 in the previous period, indicating a decrease of 14.06%[24] - The basic and diluted earnings per share for the current period are both CNY 1.88, down from CNY 2.10 in the previous period[21] - The total comprehensive income attributable to the parent company's owners is CNY 285,737,321.93, a decrease from CNY 321,615,639.73 in the previous period[21] Assets and Liabilities - The company's total assets increased by 1.40% to ¥4,337,514,441.31 compared to the end of the previous year[5] - Current assets as of September 30, 2025, totaled CNY 2,587,186,889.28, slightly down from CNY 2,601,436,202.31 at the end of 2024[16] - Non-current assets increased to CNY 1,750,327,552.03 as of September 30, 2025, compared to CNY 1,676,193,203.82 at the end of 2024[17] - Total assets reached CNY 4,337,514,441.31, up from CNY 4,277,629,406.13 at the end of 2024[18] - Total liabilities decreased to CNY 1,737,330,864.95 from CNY 1,827,290,163.33 in the previous year[18] - Shareholders' equity increased to CNY 2,600,183,576.36 as of September 30, 2025, compared to CNY 2,450,339,242.80 at the end of 2024[18] - Cash and cash equivalents stood at CNY 175,220,075.80, up from CNY 163,173,887.90 at the end of 2024[16] - Accounts receivable rose to CNY 865,583,203.16 from CNY 807,667,332.99 in the previous year[16] - Inventory decreased to CNY 309,658,226.06 from CNY 354,311,612.84 at the end of 2024[16] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥139,050,345.38, an increase of 31.45%[10] - The net cash flow from operating activities is CNY 139,050,345.38, an increase from CNY 105,781,248.03 in the previous period[24] - The company reported a net cash outflow from financing activities of CNY -171,646,633.27, worsening from CNY -97,605,918.79 in the previous period[25] - The cash and cash equivalents at the end of the period stand at CNY 150,831,297.54, down from CNY 180,774,348.01 in the previous period[25] Segment Performance - The pharmaceutical manufacturing segment saw a revenue increase of 19.67% year-to-date, while the pharmaceutical commerce segment experienced a decline of 36.91%[8] - The net profit attributable to shareholders for the year-to-date period was ¥285,737,321.93, down 11.16% year-on-year, primarily due to reduced investment income from joint ventures and non-recurring gains and losses[8] Research and Development - Research and development expenses increased to CNY 78,318,937.23, up 29.66% from CNY 60,448,309.19 in the previous period[21]

智通财经APP讯，健民集团(600976.SH)披露2025年第三季度报告，公司前三季度实现营收25.52亿元， 同比下降11.43%;归属于上市公司股东的净利润2.86亿元，同比下降11.16%;扣非净利润2.56亿元，同比 下降5.58%;基本每股收益1.88元。 ...

前三季度公司营业收入同比下降11.43%，其中医药工业同比增长19.67%，主要是公司主导产品及新产 品收入增长所致；医药商业收入同比下降36.91%，主要是公司持续优化下属商业子公司业务结构，逐 步收缩了部分低毛低效的业务，导致医药商业板块业务收入有所下降。 格隆汇10月21日丨健民集团(600976.SH)公布，公司前三季度实现营业收入25.52亿元，同比下降 11.43%；归属于上市公司股东的净利润2.86亿元，同比下降11.16%；归属于上市公司股东的扣除非经常 性损益的净利润2.56亿元，同比下降5.58%；基本每股收益1.88元。 ...

健民集团公告，第三季度营收为7.47亿元，下降14.27%；净利润为6511.17万元，下降20.84%。前三季 度营收为25.52亿元，下降11.43%；净利润为2.86亿元，下降11.16%。 ...

Core Points - Jianmin Group's stock price increased by 2.06% on October 21, reaching 40.58 CNY per share, with a total market capitalization of 6.225 billion CNY [1] - The company has experienced a 0.49% decline in stock price year-to-date, with a 2.14% increase over the last five trading days [2] - Jianmin Group's main business involves the research, manufacturing, wholesale, and retail of pharmaceuticals, with 99.47% of revenue coming from product sales [2] Financial Performance - For the first half of 2025, Jianmin Group reported operating revenue of 1.805 billion CNY, a year-on-year decrease of 10.20%, and a net profit attributable to shareholders of 221 million CNY, down 7.83% year-on-year [2] - The company has distributed a total of 1.114 billion CNY in dividends since its A-share listing, with 476 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.30% to 17,000, while the average circulating shares per person decreased by 22.66% to 9,011 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 203.04 million shares, and new entrant Rongtong Health Industry Flexible Allocation Mixed A/B [3]

Core Viewpoint - The company will hold an investor briefing on October 22, 2025, to discuss its Q3 2025 financial results and address common investor concerns [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for October 22, 2025, from 16:00 to 17:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Participants will include the company's chairman, independent directors, president, CFO, and board secretary [4]. Group 2: Participation Information - Investors can join the briefing online via the Shanghai Stock Exchange Roadshow Center [5]. - Questions can be submitted from October 15 to October 21, 2025, through the Roadshow Center's website or via the company's email [5]. - The company will respond to commonly asked questions during the briefing [3][5]. Group 3: Contact Information - Contact persons for inquiries are Cao Hong and Wang Miao, with a provided phone number [6]. - The company's email for investor questions is ir.jmjt@whjm.com [6]. Group 4: Additional Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [7]. - The company expresses gratitude for investor support and encourages participation in the online briefing [7].

证券代码：600976 证券简称：健民集团 公告编号：2025-035 健民药业集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 (一) 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 (二) 会议召开地点：上海证券交易所上证路演中心 (三) 会议召开方式：上证路演中心网络文字互动 三、参加人员 公司董事长袁平东先生、独立董事郭云沛先生、 ...

截至发稿，健民集团市值为62亿元。 每经头条（nbdtoutiao）——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后，这些城市怎么 样了？ 每经AI快讯，健民集团（SH 600976，收盘价：40.29元）10月10日晚间发布关于对子公司银行授信额度 提供担保的实施公告。公告称，截至本公告披露日，公司对控股子公司提供的担保总额度为3.56亿元 （含本次），占公司2024年经审计净资产约24.35亿元的14.62%，截至2025年9月30日，公司对控股子公 司提供的担保余额为1.27亿元。 2024年1至12月份，健民集团的营业收入构成为：医药工业占比49.83%，医药商业占比49.56%，其他业 务占比0.6%。 （记者 王可然） ...

证券代码：600976 证券简称：健民集团 公告编号：2025-034 健民药业集团股份有限公司 关于对子公司银行授信额度提供担保的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别风险提示：公司本次担保的担保对象维生公司的资产负债率超过 70%， 敬请广大投资者注意担保风险。 为支持子公司业务发展，公司将为全资子公司武汉健民药业集团维生药品有 限责任公司（以下简称：维生公司）向中信银行股份有限公司武汉分行申请的综 合授信敞口额度提供连带责任保证。现将有关情况公告如下： 重要内容提示： 被担保人为全资子公司武汉健民药业集团维生药品有限责任公司（以下简 称：维生公司）； 公司本次为维生公司提供的担保金额为 5,000 万元，截至本公告披露日公 司已实际为维生公司提供的担保余额为 0 元； 一、担保情况概述 （一）担保情况简介 被担保人：武汉健民药业集团维生药品有限责任公司 债权人：中信银行股份有限公司武汉分行 担保金额：5,000 万元 担保方式：连带责任保证 担保期限：一年 担保情况：公司为维生公司向中信银行 ...